Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific executive share transaction rather than consolidated financial performance.
Material Changes
The filing details a transaction involving Mr. Simon Dingemans, an Executive Director:
- Date of Transaction: May 6, 2016
- Instrument: Exercise of nil cost options over 19,008 ordinary shares.
- Grant Date: February 28, 2013
- Vesting Date: February 28, 2016
- Plan: GlaxoSmithKline Deferred Annual Bonus Plan
- Shares Delivered: 9,894 ordinary shares (net of tax value).
- Share Price: The fair market value at the point of exercise was £14.50 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific director transaction noted above.
Investor Verification Checklist
- Verify the total number of shares held by Mr. Simon Dingemans post-transaction.
- Confirm the tax implications and withholding calculations resulting in the delivery of 9,894 net shares.
- Review the GlaxoSmithKline Deferred Annual Bonus Plan terms regarding the vesting schedule and nil cost option structure.
- Check for any other concurrent director transactions not detailed in this specific notification.